<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03306758</url>
  </required_header>
  <id_info>
    <org_study_id>B2017-136R</org_study_id>
    <nct_id>NCT03306758</nct_id>
  </id_info>
  <brief_title>The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout</brief_title>
  <official_title>The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the serum uric acid lowering effect of sodium bicarbonate as well as its
      safety in patients with asymptomatic hyperuricemia or gout. Half of the participants will
      receive sodium bicarbonate only, while the other half receive none.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum uric acid</measure>
    <time_frame>1 month after randomization</time_frame>
    <description>Change from baseline serum levels of uric acid at 1 month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fraction excretion of uric acid</measure>
    <time_frame>1 month after randomization</time_frame>
    <description>Change from baseline fraction excretion of uric acid at 1 month</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Asymptomatic Hyperuricemia</condition>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Experimental: sodium bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Bicarbonate</intervention_name>
    <description>Sodium Bicarbonate was given 1g tid for one month</description>
    <arm_group_label>Experimental: sodium bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign informed consent form;

          2. Serum uric acid ≥420mmol/L;

          3. Within the age range of 18-65 years old;

          4. Within the BMI range of 18-30kg/m2;

          5. Both men and women are eligible

        Exclusion Criteria:

          1. General situations

               -  Pregnancy or lactation；

               -  Participants who can't take contraception during the study or within one month
                  after the completion of the intervention;

               -  Situations which will harm the participants;

               -  Participants with bad compliance.

          2. Taking part in another trail

          3. Gout flares happening over the last one month;

          4. Administration of medications over the last one month, including: allopurinol,
             Febuxostat,benzbromarone, and/or sodium bicarbonate；

          5. urine pH&gt;7.0;

          6. Hepatic function：ALT and/or AST and/or TB＞1.5 upper limit of normal (ULN);

          7. Renal function：eGFR＜60 ml/min for MDRD and/or urine protein&gt;0.5g/24h；

          8. Hypertension：&gt;140/90mmHg;

          9. Type 2 diabetes or taking drugs for lowering glucose (not including prediabetes);

         10. Urinary stone,urinary infection;

         11. Taking drugs ove the last one month and during the trial, including：thiazide diuretic,
             Loop diuretics, pyrazinamide,ethambutol, tacrolimus, niacin, aspirin, estrogen,
             losartan, amlodipine, reserpine, vitamin C，fenofibrate，atorvastatin，
             sulfonylureas，biguanides，NSAIDs;

         12. Disease which influence serum uric acid, such as cancer, lymphoma, and etc.

         13. Severe disorders involving heart, liver, kidneys, brain, lungs,digestive tract,
             rheumatoid disease, blood, endocrine, infection, and etc;

         14. Blood donation or excessive loss of blood over the last 3 month.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Jiang lindi</investigator_full_name>
    <investigator_title>Chief, Professor, Department of Rheumatology, Shanghai Zhongshan Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

